Zenas BioPharma, Inc. (ZBIO): Cash & Equivalents
$110.64M
As of 2025-12-31
$196.58M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $110.64M | -65.4% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $319.74M | +462.4% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $56.86M | n/a | 2025-03-11, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $110.64M | -65.4% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $52.33M | -87.8% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $30.23M | +2.4% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $307.53M | -34.8% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $213.19M | +513.2% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $188.89M | -46.7% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $968.0K | -87.9% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $1.42B | -47.7% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $35.26M | +182.6% |
Compare ZBIO, JANX, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗